These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 25600995)

  • 1. Improvement of dizocilpine-induced social recognition deficits in mice by brexpiprazole, a novel serotonin-dopamine activity modulator.
    Yoshimi N; Futamura T; Hashimoto K
    Eur Neuropsychopharmacol; 2015 Mar; 25(3):356-64. PubMed ID: 25600995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors.
    Yoshimi N; Fujita Y; Ohgi Y; Futamura T; Kikuchi T; Hashimoto K
    Pharmacol Biochem Behav; 2014 Sep; 124():245-9. PubMed ID: 24955861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator.
    Maeda K; Sugino H; Akazawa H; Amada N; Shimada J; Futamura T; Yamashita H; Ito N; McQuade RD; Mørk A; Pehrson AL; Hentzer M; Nielsen V; Bundgaard C; Arnt J; Stensbøl TB; Kikuchi T
    J Pharmacol Exp Ther; 2014 Sep; 350(3):589-604. PubMed ID: 24947465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator.
    Maeda K; Lerdrup L; Sugino H; Akazawa H; Amada N; McQuade RD; Stensbøl TB; Bundgaard C; Arnt J; Kikuchi T
    J Pharmacol Exp Ther; 2014 Sep; 350(3):605-14. PubMed ID: 24947464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different MK-801 administration schedules induce mild to severe learning impairments in an operant conditioning task: role of buspirone and risperidone in ameliorating these cognitive deficits.
    Rapanelli M; Frick LR; Bernardez-Vidal M; Zanutto BS
    Behav Brain Res; 2013 Nov; 257():156-65. PubMed ID: 24095879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia.
    Pichat P; Bergis OE; Terranova JP; Urani A; Duarte C; Santucci V; Gueudet C; Voltz C; Steinberg R; Stemmelin J; Oury-Donat F; Avenet P; Griebel G; Scatton B
    Neuropsychopharmacology; 2007 Jan; 32(1):17-34. PubMed ID: 16936709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. D-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats.
    Karasawa J; Hashimoto K; Chaki S
    Behav Brain Res; 2008 Jan; 186(1):78-83. PubMed ID: 17854919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brexpiprazole as adjunctive treatment of major depressive disorder with anxious distress: Results from a post-hoc analysis of two randomised controlled trials.
    McIntyre RS; Weiller E; Zhang P; Weiss C
    J Affect Disord; 2016 Sep; 201():116-23. PubMed ID: 27208498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of selective antagonists of serotonin 5-HT7 and 5-HT1A receptors on MK-801-induced impairment of learning and memory in the passive avoidance and Morris water maze tests in rats: mechanistic implications for the beneficial effects of the novel atypical antipsychotic lurasidone.
    Horisawa T; Ishibashi T; Nishikawa H; Enomoto T; Toma S; Ishiyama T; Taiji M
    Behav Brain Res; 2011 Jun; 220(1):83-90. PubMed ID: 21277905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MK-801-induced deficits in social recognition in rats: reversal by aripiprazole, but not olanzapine, risperidone, or cannabidiol.
    Deiana S; Watanabe A; Yamasaki Y; Amada N; Kikuchi T; Stott C; Riedel G
    Behav Pharmacol; 2015 Dec; 26(8 Spec No):748-65. PubMed ID: 26287433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brexpiprazole: First Global Approval.
    Greig SL
    Drugs; 2015 Sep; 75(14):1687-97. PubMed ID: 26310190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potentiation of neurite outgrowth by brexpiprazole, a novel serotonin-dopamine activity modulator: a role for serotonin 5-HT1A and 5-HT2A receptors.
    Ishima T; Futamura T; Ohgi Y; Yoshimi N; Kikuchi T; Hashimoto K
    Eur Neuropsychopharmacol; 2015 Apr; 25(4):505-11. PubMed ID: 25687838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antipsychotic drug perospirone: role of serotonin 5-HT1A receptors.
    Hagiwara H; Fujita Y; Ishima T; Kunitachi S; Shirayama Y; Iyo M; Hashimoto K
    Eur Neuropsychopharmacol; 2008 Jun; 18(6):448-54. PubMed ID: 18164909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of action of brexpiprazole: comparison with aripiprazole.
    Stahl SM
    CNS Spectr; 2016 Feb; 21(1):1-6. PubMed ID: 26899451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of brexpiprazole adjunctive treatment for major depressive disorder.
    Sussman M; Yu J; Kamat SA; Hartry A; Legacy S; Duffy R; Aigbogun MS
    J Affect Disord; 2017 Jan; 207():54-62. PubMed ID: 27693466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brexpiprazole for the treatment of schizophrenia.
    Yee A
    Expert Rev Neurother; 2016; 16(2):109-22. PubMed ID: 26650624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brexpiprazole reduces hyperactivity, impulsivity, and risk-preference behavior in mice with dopamine transporter knockdown-a model of mania.
    Milienne-Petiot M; Geyer MA; Arnt J; Young JW
    Psychopharmacology (Berl); 2017 Mar; 234(6):1017-1028. PubMed ID: 28160035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brexpiprazole for the treatment of schizophrenia.
    Hsu WY; Lane HY; Lin CH
    Expert Opin Pharmacother; 2017 Feb; 18(2):217-223. PubMed ID: 27997809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol.
    Gomes FV; Llorente R; Del Bel EA; Viveros MP; López-Gallardo M; Guimarães FS
    Schizophr Res; 2015 May; 164(1-3):155-63. PubMed ID: 25680767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Translating the N-methyl-D-aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia.
    Meltzer HY; Rajagopal L; Huang M; Oyamada Y; Kwon S; Horiguchi M
    Int J Neuropsychopharmacol; 2013 Nov; 16(10):2181-94. PubMed ID: 24099265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.